Cataract treatment method

Abstract

To provide an effective treatment method for cataracts.SOLUTION: As a cataract treatment, L-aspartic acid and a gene regeneration medical drug that is obtained by production methods described in Japanese Patent Application 2021-209942 "Method for Immortality" and Japanese Patent Application 2021-209943 ("Method for Producing Gene Therapy Drugs Using Enzymes") is administered to an affected area in a condition suitable for the body, optionally with a suitable supplement of α-crystallin, β-crystallin and γ-crystallin in a condition suitable for the body.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a method for treating cataracts.

Background Art

[0002] Conventionally, research and treatment methods for cataracts have advanced, but a method for treating cataracts using the method of the present invention has not yet been devised. This invention relates to a method for treating cataracts.

[0003]

Non-Patent Document 1

Non-Patent Document 2

Non-Patent Document 3

Non-Patent Document 4

Non-Patent Document 5

Non-Patent Document 6

Summary of the Invention

Problems to be Solved by the Invention

[0004] Effective method for treating cataracts

Means for Solving the Problems

[0005] Cataracts develop when crystallin, a protein that makes up the lens, aggregates and denatures, becoming cloudy in yellowish - white or white color. It has been pointed out that the cause of crystallin aggregation is the change of aspartic acid contained in α - crystallin from the L - form to the D - form (racemization). α - crystallin has been found to have a function (chaperone) of returning partially denatured β - and γ - crystallin to normal and preventing aggregation. On the other hand, β - and γ - crystallin have functions of maintaining the transparency of the lens and increasing the refractive index of light. In mammals, crystallin is a mixture of three types of proteins: α, β, and γ. In humans, the ratio of crystallin in the lens is 45% α, 20% β, and 35% γ. Therefore, when administering crystallin to supplement the deficiency, the formulation is adjusted according to this ratio. For cataract treatment, in a state suitable for the body, a gene regenerative medicine prepared by the manufacturing methods of Japanese Patent Application No. 2021 - 209942 "Method of Immortality" and Japanese Patent Application No. 2021 - 209943 "Method for Producing a Gene Therapy Agent Using Enzymes", and L - aspartic acid is administered to the affected area. If necessary, α - crystallin, β - crystallin, and γ - crystallin are supplemented in a state suitable for the body as appropriate.

Effects of the Invention

[0006] Effective cataract treatment can be achieved.

Modes for Carrying Out the Invention

[0007] For the treatment of cataracts, a gene regenerative medical drug manufactured by the manufacturing method described in Patent Application No. 2021-209942 "Method of immortality" and Patent Application No. 2021-209943 "Manufacturing method of gene therapy drug using enzymes", as well as aspartic acid L, are administered to the affected area in a state suitable for the body, and if necessary, alpha crystallin, beta crystallin, and gamma crystallin are appropriately replenished in a state suitable for the body. EXAMPLES

[0008] It is carried out as described above. [Industrial Applicability]

[0009] The effective cataract treatment method described in this specification, which combines a series of techniques, has industrial applicability.

Claims

[Claim 1] Patent application No. 2021-209942 "Method of immortality", Patent application No. 2021-209943 "Method of producing gene therapy drug using enzyme", Cataract treatment using aspartic acid L, α-crystallin, β-crystallin, and γ-crystallin